Management Hibernaid In the News

Contact us for more information

Stephen J. PettiStephen J. Petti
Chief Executive Officer

Stephen J. Petti is the Company's Chief Executive Officer. He was formerly the Founder and CEO of Blue Note Pharmaceuticals, and prior to that, Empire Pharmaceuticals, acquired by a publicly traded company in 2004, where Mr. Petti went on to lead the Company's stroke program and also served as the President of the subsidiary business entity that was created post-merger. Mr. Petti also participated in the start-up phase of DOV Pharmaceutical, a CNS specialty Pharma company, which he helped guide from first money through IPO in the space of three years. While at DOV he also served as the President of two major product development collaborations involving Elan and Biovail. Mr. Petti has 25 years of international clinical drug development experience in a variety of settings that include Big- Mid- and Small- Pharma entities and major CROs. Over the course of his career he has participated in six successful NDAs/PLAs over a wide range of therapeutic areas and clinical indications. In the CRO arena, he served as Vice President of Global Clinical Consulting at Barnett International, a subsidiary of Parexel International, in the process establishing the company's first overseas office in Paris, the headquarters from which he managed the company's European operations. A former critical-care R.N. (BSN), Mr. Petti is a Fellow of the American Heart Association and the Stroke Council and a member of the American Society of Hypertension and the Society of Critical Care Medicine. He is active in entrepreneurial mentorship through Rensselaer Polytechnic Institute in Troy, NY and serves as Board Chairman for Vital Vio, Inc., a company developing bactericidal lighting for the hospital market.

Email him at

Laurence Katz, M.D.Laurence M. Katz, M.D.
Founder, Chief Scientific Officer, Chief Medical/Scientific Consultant to the CEO

Laurence M. Katz, M.D., is Hibernaid's Founder and serves as special medical/scientific consultant to the CEO. Dr. Katz is Associate Professor of Emergency Medicine at the University of North Carolina at Chapel Hill, where he also managed the translational research program that produced the discovery of HBN-1 and the completion of a comprehensive 6 year pre-clinical program studying and refining its controlled hypothermia properties. Dr. Katz is Co-Director of the Carolina Resuscitation Research Group and also has extensive experience running acute medicine clinical trials (hospital and pre-hospital).

Email him at

Samn RaffanielloSamn Raffaniello
Director, Administration and Project Services

Samn Raffaniello is Director of Administration and Project Services. Ms Raffaniello has co-founded three start-ups in the past 12 years where her operational roles included project management/systems; budget/finance; drug manufacturing oversight; and contracts and IP management. A graduate of the University of Maryland, Ms Raffaniello has 10 years prior experience in technical and business support of global drug development.

Email her at